Researchers face patent race for breast cancer geneBMJ 1996; 312 doi: http://dx.doi.org/10.1136/bmj.312.7022.12 (Published 06 January 1996) Cite this as: BMJ 1996;312:12
- Owen Dyer
A team of Anglo-American researchers who recently announced their discovery of a second gene that causes breast cancer now seems likely to face a challenge from a rival American project. Myriad Genetics, based in Salt Lake City, Utah, claims to have beaten the Institute of Cancer Research in a race to isolate the gene BRCA2 and has filed an application for a US patent.
The British team, led by Dr Mike Stratton of the Institute of Cancer Research, has also filed a preliminary application for a European patent in the name of CRC Technology, the institute's technology transfer company. Myriad Genetics, meanwhile, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial